Correction: EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis

Documenti analoghi

• Recent Advances in the Management of EGFR-Mutated Advanced Non-Small Cell Lung Cancer—A Narrative Review
  di: Prabhat Gautam Roy, et al.
  Pubblicazione: (2025-08-01)
• Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC
  di: Yingqi Xu, et al.
  Pubblicazione: (2025-12-01)
• Correction: EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
  di: Ao Liu, et al.
  Pubblicazione: (2025-01-01)
• Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option?
  di: Paolo Maione, et al.
  Pubblicazione: (2026-01-01)
• Cost-effectiveness analyses of amivantamab plus lazertinib and lazertinib versus osimertinib in non-small cell lung cancer with EGFR mutations
  di: Hui Zhang, et al.
  Pubblicazione: (2025-05-01)